| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/12/2023 | 212.77% | Truist Securities | $20 → $18 | Maintains | Buy |
| 06/26/2023 | 386.53% | Oppenheimer | → $28 | Assumes | → Outperform |
| 06/20/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 06/16/2023 | 508.17% | Canaccord Genuity | → $35 | Reiterates | Buy → Buy |
| 06/05/2023 | 160.64% | JMP Securities | → $15 | Reiterates | → Market Outperform |
| 06/05/2023 | 160.64% | EF Hutton | → $15 | Reiterates | Buy → Buy |
| 05/26/2023 | 160.64% | EF Hutton | → $15 | Reiterates | Buy → Buy |
| 05/05/2023 | 160.64% | JMP Securities | $19 → $15 | Maintains | Outperform |
| 05/05/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 05/04/2023 | 30.32% | Stifel | $8 → $7.5 | Maintains | Hold |
| 05/04/2023 | 160.64% | RBC Capital | → $15 | Reiterates | → Outperform |
| 04/20/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/18/2023 | 230.15% | JMP Securities | → $19 | Reiterates | → Market Outperform |
| 04/17/2023 | 160.64% | EF Hutton | → $15 | Maintains | Buy |
| 04/04/2023 | 299.65% | HC Wainwright & Co. | $29 → $23 | Maintains | Buy |
| 03/21/2023 | 4.26% | Bernstein | → $6 | Initiates Coverage On | → Market Perform |
| 03/02/2023 | 438.66% | Goldman Sachs | $35 → $31 | Maintains | Buy |
| 03/02/2023 | 230.15% | JMP Securities | $23 → $19 | Maintains | Market Perform |
| 03/01/2023 | 282.28% | RBC Capital | $32 → $22 | Maintains | Outperform |
| 03/01/2023 | 386.53% | Oppenheimer | $32 → $28 | Maintains | Outperform |
| 03/01/2023 | 438.66% | Goldman Sachs | $35 → $31 | Maintains | Buy |
| 03/01/2023 | 160.64% | EF Hutton | → $15 | Reiterates | → Buy |
| 01/24/2023 | 91.14% | JP Morgan | $20 → $11 | Upgrades | Neutral → Overweight |
| 01/06/2023 | 108.51% | Baird | → $12 | Upgrades | Neutral → Outperform |
| 01/05/2023 | 160.64% | EF Hutton | → $15 | Initiates Coverage On | → Buy |
| 12/12/2022 | 56.39% | B of A Securities | → $9 | Downgrades | Buy → Underperform |
| 11/21/2022 | 403.91% | HC Wainwright & Co. | $43 → $29 | Maintains | Buy |
| 09/22/2022 | 212.77% | B. Riley Securities | $21 → $18 | Maintains | Buy |
| 08/10/2022 | 508.17% | Oppenheimer | $40 → $35 | Maintains | Outperform |
| 08/10/2022 | 456.04% | RBC Capital | $35 → $32 | Maintains | Outperform |
| 08/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 07/15/2022 | 456.04% | Goldman Sachs | $9 → $32 | Upgrades | Neutral → Buy |
| 06/03/2022 | 91.14% | Baird | → $11 | Initiates Coverage On | → Neutral |
| 05/24/2022 | 56.39% | Goldman Sachs | $12 → $9 | Maintains | Neutral |
| 05/05/2022 | 125.89% | Raymond James | $36 → $13 | Maintains | Outperform |
| 03/07/2022 | 108.51% | Goldman Sachs | $20 → $12 | Maintains | Neutral |
| 12/14/2021 | 508.17% | RBC Capital | $45 → $35 | Maintains | Outperform |
| 10/12/2021 | 369.16% | JMP Securities | $53 → $27 | Maintains | Market Outperform |
| 10/08/2021 | — | Stifel | Downgrades | Buy → Hold | |
| 10/08/2021 | 681.93% | RBC Capital | $55 → $45 | Maintains | Outperform |
| 10/08/2021 | 247.52% | Goldman Sachs | $71 → $20 | Downgrades | Buy → Neutral |
| 09/24/2021 | 525.54% | Raymond James | → $36 | Upgrades | Market Perform → Outperform |
| 09/23/2021 | 525.54% | Raymond James | → $36 | Upgrades | Market Perform → Outperform |
| 05/20/2021 | 612.42% | Truist Securities | $34 → $41 | Upgrades | Hold → Buy |
| 05/14/2021 | 803.56% | B. Riley Securities | → $52 | Initiates Coverage On | → Buy |
| 03/01/2021 | 647.18% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 01/26/2021 | 647.18% | Stifel | $33 → $43 | Upgrades | Hold → Buy |
| 12/10/2020 | 595.05% | HC Wainwright & Co. | → $40 | Assumes | → Buy |
| 10/23/2020 | 855.69% | RBC Capital | → $55 | Initiates Coverage On | → Outperform |
| 06/12/2020 | 751.43% | HC Wainwright & Co. | $55 → $49 | Maintains | Buy |
| 06/01/2020 | 855.69% | Oppenheimer | $50 → $55 | Maintains | Outperform |
| 06/01/2020 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 05/19/2020 | 942.57% | Roth Capital | → $60 | Upgrades | Neutral → Buy |
| 05/15/2020 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 05/14/2020 | 664.55% | Canaccord Genuity | $36 → $44 | Maintains | Buy |
| 05/14/2020 | 768.81% | Oppenheimer | $44 → $50 | Maintains | Outperform |
| 05/14/2020 | 629.8% | HC Wainwright & Co. | $35 → $42 | Reiterates | → Buy |
| 05/14/2020 | 456.04% | SunTrust Robinson Humphrey | $29 → $32 | Downgrades | Buy → Hold |
| 04/13/2020 | 403.91% | SunTrust Robinson Humphrey | → $29 | Initiates Coverage On | → Buy |
| 02/24/2020 | 369.16% | Berenberg | → $27 | Initiates Coverage On | → Hold |
| 12/18/2019 | 542.92% | JMP Securities | → $37 | Initiates Coverage On | → Market Outperform |
| 11/04/2019 | 525.54% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
| 08/09/2019 | 542.92% | BTIG | → $37 | Initiates Coverage On | → Buy |
| 06/05/2019 | 351.78% | Roth Capital | → $26 | Initiates Coverage On | → Neutral |
| 05/31/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 05/23/2019 | 369.16% | Stifel | → $27 | Initiates Coverage On | → Hold |
| 05/03/2019 | 681.93% | Oppenheimer | → $45 | Initiates Coverage On | → Outperform |
| 03/29/2019 | 768.81% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 03/15/2019 | 595.05% | Raymond James | → $40 | Initiates Coverage On | → Outperform |
| 03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/05/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/05/2018 | 403.91% | JP Morgan | → $29 | Initiates Coverage On | → Neutral |
| 11/05/2018 | 438.66% | Jefferies | → $31 | Initiates Coverage On | → Buy |
| 11/05/2018 | 612.42% | Goldman Sachs | → $41 | Initiates Coverage On | → Buy |
What is the target price for Allogene Therapeutics (ALLO)?
The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by Truist Securities on July 12, 2023. The analyst firm set a price target for $18.00 expecting ALLO to rise to within 12 months (a possible 212.77% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Allogene Therapeutics (ALLO)?
The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by Truist Securities, and Allogene Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
Is the Analyst Rating Allogene Therapeutics (ALLO) correct?
While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a maintained with a price target of $20.00 to $18.00. The current price Allogene Therapeutics (ALLO) is trading at is $5.76, which is out of the analyst's predicted range.